Engineering effective T-cell based antitumor immunity

Oncoimmunology. 2013 Feb 1;2(2):e22893. doi: 10.4161/onci.22893.


The adoptive transfer of synthetic siRNA-mediated cblb-depleted autologous CD8+ T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augment the effectiveness of adoptively transferred immune cells.

Keywords: RNA interference; cancer immunotherapy; cblb; engineered T cells; reinforced anti-tumor functions.